The number of legal disputes regarding the infringement of intellectual rights for drugs in 2022-2026 exceeded 150, which is almost five times more than the previous five years, Kommersant writes, citing calculations by the International Pharmaceutical Manufacturers Association. The emphasis in the proceedings has shifted from challenging patents to the early release of generic drugs and obtaining compulsory licenses. In total, since 2017, more than 180 cases have been opened regarding 51 drugs, more than 50 of which are still under consideration.